Choriocarcinoma
10
2
4
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
10.0%
1 terminated out of 10 trials
75.0%
-11.5% vs benchmark
20%
2 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Molecular Epidemiology of Pediatric Germ Cell Tumors
Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Clinical Database and Biobank of Patients With Gynecologic Neoplasms
TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
A Trial for Patients With Gestational Trophoblastic Disease
Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma